Tumour Immune Landscape Predicts Chemotherapy Response in Colorectal Cancer Surgery
A new study in *The Pharmacogenomics Journal* investigates the critical link between the tumour immune microenvironment and the efficacy of standard chemotherapy regimens in colorectal cancer. The research focuses on how the level and type of immune cell infiltration within a tumour can predict patient response to FOLFOX or FOLFIRI chemotherapy, which are cornerstone treatments often used in the perioperative setting for colorectal cancer. This analysis moves beyond traditional staging to offer a potential biomarker for personalizing adjuvant or neoadjuvant treatment strategies, directly impacting surgical oncology planning and postoperative care protocols to improve long-term surgical outcomes and reduce recurrence.
Study Significance: For surgical oncologists, this research provides a tangible link between tumour biology and therapeutic decision-making. Assessing the immune contexture of a resected tumour could guide the selection of the most effective postoperative chemotherapy, enhancing recovery protocols and personalizing cancer care. This biomarker-driven approach represents a shift towards integrating detailed molecular pathology into standard surgical practice to optimize patient survival and minimize ineffective treatments.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
